Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelogenous leukemia

H Enright1, P B McGlave

  • 1Department of Medicine, University of Minnesota Hospital, Minneapolis 55455, USA.

Current Opinion in Hematology
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis B screening in hematology patients receiving intravenous immunoglobulin.

Transfusion·2024
Same author

Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices.

Thrombosis update·2024
Same author

Incidence of cutaneous T-cell lymphoma in the Republic of Ireland between 1994 and 2019.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Controlled placement of multiple CNS cell populations to create complex neuronal cultures.

PloS one·2017
Same author

Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

Safety and efficacy of ruxolitinib in a profoundly thrombocytopenic patient with myelofibrosis.

Annals of hematology·2014

Chronic myelogenous leukemia (CML) is driven by the bcr-abl oncoprotein. Current therapies like interferon alpha and stem cell transplantation offer survival benefits, with future treatments focusing on targeted stem cell therapies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome (Ph), a translocation between chromosomes 9 and 22.
  • This translocation generates the aberrant bcr-abl fusion protein, which possesses enhanced tyrosine kinase activity.
  • The bcr-abl protein drives clonal expansion of hematopoietic progenitor cells, leading to uncontrolled cell proliferation, transformation, and suppressed apoptosis.

Purpose of the Study:

  • To review the pathogenesis of CML, focusing on the role of aberrant bcr-abl protein and stromal cell interactions.
  • To summarize current therapeutic strategies, including interferon alpha and allogeneic marrow transplantation.
  • To discuss emerging therapeutic approaches and areas of ongoing research in CML.

Main Methods:

Related Experiment Videos

  • Literature review of studies on CML pathogenesis and treatment.
  • Analysis of data on the efficacy of interferon alpha therapy.
  • Evaluation of outcomes for allogeneic, unrelated donor, and autologous marrow transplantation.
  • Review of preclinical research on antisense oligonucleotides and immunologic responses.

Main Results:

  • Interferon alpha yields hematologic responses in 70-80% and cytogenetic responses in up to 50% of chronic-phase CML patients, improving survival.
  • Allogeneic marrow transplantation offers long-term survival, especially in younger patients treated early.
  • Unrelated donor or autologous marrow transplantation are viable options for patients lacking a matched sibling donor.

Conclusions:

  • Therapeutic strategies for CML have evolved, with significant improvements in patient outcomes.
  • Future CML therapy may involve ex vivo selection and expansion of Philadelphia chromosome-negative (Ph-) stem cells for autologous transplantation.
  • Ongoing research into novel agents like antisense oligonucleotides and immunotherapies holds promise for further advancing CML treatment.